Table 2.
Univariate and multivariate analyses of factors associated with FFLP and OS
| FFLP |
OS |
|||||||
|---|---|---|---|---|---|---|---|---|
| Univariate |
Multivariate |
Univariate |
Multivariate |
|||||
| Variable | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P |
| Female sex (vs male) | 1.44 (0.84-2.46) | .188 | - | - | 0.82 (0.45-1.47) | .498 | - | - |
| Age at RT | 1.01 (0.99-1.03) | .197 | - | - | 1.01 (0.99-1.03) | .552 | - | - |
| M1 stage at diagnosis (vs M0) | 0.68 (0.39-1.19) | .181 | - | - | 0.87 (0.49-1.54) | .631 | - | - |
| ≥2 hepatic lesions at RT (vs 1) | 1.54 (0.89-2.67) | .122 | - | - | 1.88 (1.07-3.28) | .027⁎ | 1.79 (0.99-3.23) | .052⁎ |
| Extrahepatic disease at RT (vs none) | 1.19 (0.69-2.04) | .535 | - | - | 4.10 (1.96-8.55) | <.001⁎ | 1.89 (0.79-4.51) | .2 |
| BED10 < 96 Gy (vs ≥96 Gy) | 2.69 (1.54-4.68) | <.001⁎ | 1.83 (0.98-3.42) | .057⁎ | 2.35 (1.35-4.09) | .002⁎ | 2.10 (1.17-3.76) | .013⁎ |
| Size above median 2.9 cm (vs <2.9 cm) | 2.30 (1.33-4.0) | .003⁎ | 1.94 (1.04-3.60) | .037⁎ | 2.81 (1.56-5.06) | <.001⁎ | 1.89 (0.98-3.63) | .058⁎ |
| CEA at RT | 1.10 (0.97-1.26) | .148 | - | - | 1.53 (1.32-1.77) | <.001⁎ | 1.31 (1.10-1.57) | .002⁎ |
| ≥3 lines of chemo (vs <3) | 2.67 (1.50-4.74) | <.001⁎ | 2.58 (1.42-4.66) | .002⁎ | 4.70 (2.37-9.31) | <.001⁎ | 2.78 (1.31-5.91) | .008⁎ |
| Liver-directed therapy (vs none) | 0.84 (0.40-1.80) | .658 | - | - | 0.56 (0.29- 1.11) | .098 | - | - |
| KRAS (vs wild type) | 0.47 (0.22-0.97) | .042⁎ | - | - | 1.71 (0.89-3.31) | .108 | - | - |
Abbreviations: BED = biologically effective dose; CEA = carcinoembryonic antigen; FFLP = freedom from local progression; HR = hazard ratio; OS = overall survival; RT = radiation therapy.
⁎
P values that are statistically significant or suggestive of a trend.